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Sequence-selective Q1 Q2DNA recognition and
enhanced cellular up-take by peptide–steroid
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Benoit Louage,c Malgorzata Honcharenko,d Bruno G. De Geest,c
C. I. Edvard Smith,b Roger Stro¨mbergd and Annemieke Madder*a
Several GCN4 bZIP TF models have previously been designed and
synthesized. However, the synthetic routes towards these constructs
are typically tedious and diﬃcult. We here describe the substitution
of the Leucine zipper domain of the protein by a deoxycholic acid
derivative appending the two GCN4 binding region peptides through
an optimized double azide–alkyne cycloaddition click reaction. In
addition to achieving sequence specific dsDNA binding, we have
investigated the potential of these compounds to enter cells. Con-
focal microscopy and flow cytometry show the beneficial influence
of the steroid on cell uptake. This unique synthetic model of the bZIP
TF thus combines sequence specific dsDNA binding properties with
enhanced cell-uptake. Given the unique properties of deoxycholic
acid and the convergent nature of the synthesis, we believe this work
represents a key achievement in the field of TF mimicry.
Gene expression at the transcriptional level is mainly regulated
by proteins that bind DNA in a sequence-specific manner.
These proteins, known as transcription factors (TFs), are
responsible for controlling the transfer of genetic information
from DNA to mRNA. More specifically, many oncoproteins are
transcription factors responsible for cell-growth proliferation
and tumor formation.1 As a consequence of the specificity of
these oncoproteins in the DNA sequence recognition during
transcription, several approaches have been explored to
develop inhibitors or modifiers of gene expression that can
prevent specific genes from being transcribed.2
In addition, the lack of a general recognition code for the
interaction between amino acid sequences within a protein and
its specific DNA-binding site has promoted the study of the
structure of TFs and their interaction with the DNA.3 We here
present our eﬀorts towards mimicking the GCN4 bZIP TF
(General Control Protein Leucine Zipper Transcription Factor)
by a simplified synthetic construct and towards understanding
how these protein mimics behave in a cellular context.4 The
GCN4 bZIP TF, which controls the activation of several genes in
response to amino acid starvation in yeast, has been chosen as
model system in order to allow comparison with previously
published TF miniaturisation attempts. Many eukaryotic tran-
scription factors feature homologous protein sequences form-
ing a family generally referred to as the basic-region-leucine-
zipper or bZIP motif of which the mammalian ATF/CREB family
of transcription factors represent a large group. Our target has
been to develop a new type of site-specific DNA binders which
can recognize dsDNA by specific binding in the major groove
and additionally show enhanced cellular uptake by exploiting
the unique properties of the steroid moiety. We have been
inspired by the bZIP (leucine zipper) and the b-HLH-ZIP (helix–
loop–helix leucine zipper) motifs, in which the basic DNA
recognition region binds to the major groove as a dimer,
inserting two a-helices held in the correct position by a dimer-
ization domain.5 The main residues of the protein involved in
the DNA recognition comprise the amino acids 226–248 of the
basic region of the GCN4 protein. Previously, models of such
transcription factors have been synthesized by different
research groups employing a series of different dimerization
domain substitutes. Pioneering work was carried out by the
group of Kim,6 developing an analogue in which the com-
plete dimerization domain was substituted by a simple disul-
fide bond. Building on this successful idea of miniaturisation,
Morii, Schepartz, Mascaren˜as Q3and our group have enforced the
proof-of-concept by using a variety of small dimerizing moi-
eties.7–12 Subsequently, we have shown that the attachment of
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COMMUNICATION
deoxycholic acid in this case, also allows selective recognition
of DNA. Indeed, our previous work on cMyc-Max b-HLH-ZIP
and GCN4-bZIP proteins showed that this type of steroid-based
constructs show potential for binding DNA.10,13 The specific
choice of the steroid scaffold was inspired by the fact that it is
inexpensive, commercially available, versatile and easy to mod-
ify synthetically. In addition, its known ability to enhance
proteolytic stability of attached peptides,14–16 amphiphilicity,17
the conformational properties ensuring correct positioning of
the two appended chains18 and the potential to increase
cellular uptake and bioavailability19 render it an excellent
candidate for the attachment of the two DNA recognizing arms
of the zipper motif of GCN4. The incorporation of a spacer
between the peptides and the steroid scaffold was shown
important in order to provide the final conjugate with enough
flexibility to adopt an optimal conformation for specific inter-
action with the major groove of the target DNA sequence.13
However, the concomitant further lengthening of the 23-mer
peptide chains caused increased tendency of peptide aggrega-
tion necessitating the use of microwave assistance for success-
ful synthesis.13 In order to synthesize these peptidosteroids in a
more effective and convenient way, we here explored a con-
vergent approach involving the CuAAC reaction (copper-
catalyzed alkyne–azide cycloaddition) to conjugate the recogni-
tion domains to a functionalized steroid scaffold. The geo-
metric, steric and electronic properties of the 1,2,3-triazole
resemble a trans-amide bond, while also affording resistance
to enzymatic degradation,20–23 hydrolysis and oxidation. In
addition, successful replacement of two amino acids in
a-helical peptides by a triazole unit has been shown to not
significantly influence the secondary peptide structure.20 To
date the triazole linkage has scarcely been used for peptide–
steroid conjugation and only to assemble short apolar tripep-
tides onto bile acid scaffolds,24 despite the increasing interest
of these type of conjugates in diverse applications such as HIV
inhibitors25,26 and immunogens for vaccine development.27
In the current work we have designed and synthesized four
diﬀerent scaﬀolds for peptide dimerization of the GCN4 basic
region, which was made possible by optimizing conditions for
the CuAAC mediated conjugation of the long, unprotected and
functionalized zipper peptides. A small series of deoxycholic
acid derivatives was conceived, diﬀering with respect to spacers
between the peptide and the steroid skeleton, which have
diﬀerent lengths, rigidities and functionalities. Hereto,
commercially available deoxycholic acid was modified at the
alcohol positions by attachment of diﬀerent linkers. The lin-
kers chosen for the study encompass pentynoic acid, azido
glycine, 4-azidomethyl-benzoic acid and (N-propynoylamino)-p-
toluic acid (PATA). The PATA linker has been specifically
developed for bioconjugation purposes as an active alkyne for
preparation of peptide–oligonucleotide conjugates via CuAAC.28
Functionalization of the steroid nucleus was performed by Ste-
glich esterification, affording final scaffolds (1–3). In case of PATA
as linker (4), the diamino derivative of deoxycholic acid proved
necessary for the coupling of the linker, as esterification gave rise
to byproducts due to the high reactivity of the alkyne.
The GCN4 basic DNA binding region consists of 23 amino
acids that specifically recognize the ATF/CREB binding site
(50-ATGA C/G TCAT-30), which is the functional target of
GCN4 in vivo and involved in inducing amino acid biosynthesis
in yeast.29
In order to append the peptides to the bile acid scaﬀolds,
peptides were modified at the C-terminus with unnatural
amino acids bearing an alkyne or an azide. Peptides 5 and 6
were synthesized in an automated fashion using Fmoc/tBu
based solid phase peptide synthesis (SPPS). The alkyne and
azide functionalized GCN4 basic region peptides, 5 and 6 were
then attached to the central steroid core, aﬀording four diﬀer-
ent transcription factor models. With this hydrophilic depro-
tected peptide and the hydrophobic scaﬀold, the DMSO/H2O
combination was found to be optimal for the CuAAC reaction.
As a catalyst, Cu(CH3CN)4PF6 gave the best results. A high
excess of catalyst was needed possibly due to complexation of
copper with the nitrogen containing side chains of the peptide.
However, reaction proceeds well with excess of copper ion
complex and the copper ions can be readily removed after
reaction by use of EDTA.28 An excess of scaﬀold was also
required for complete reaction of the peptide, the dipodal
construct being favoured over the monopodal one under these
conditions. The reaction was complete after 3 hours at room
temperature and compatible with the presence of all unpro-
tected amino acids in the sequence. Purification of final con-
structs after completion of the reaction was possible via
RP-HPLC, aﬀording compounds 7–10 in high purity for DNA
binding studies. DNA binding affinity of mimics 7–10 was
evaluated using an Electrophoretic Mobility Shift Assay (EMSA).
The study was based on titration of a duplex DNA sequence
containing the ATF/CREB recognition site with increasing con-
centrations of compounds Q47–10 (Fig. 1 and 2).
No clear specific binding to DNA could be observed for
mimics 8 and 10 (gel not shown). On the other hand, EMSA
for compounds 7 and 9 in the absence of any competitor DNA
shows that both compounds have a high aﬃnity for the CRE
DNA sequence (Fig. 3A). A closer visual inspection of the gels
reveals that 7 has slightly higher DNA binding aﬃnity as

























Fig. 1 Artificial DNA binder design.
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of bands even at the lowest concentration, accurate determina-
tion of the dissociation constant (KD) was not possible under
these conditions. However, by a simple visual inspection we can
conclude that almost all the DNA is completely bound at 50 nM
in case of compound 7 and at 62.5 nM in case of 9. Decreasing
the peptide concentration to a value o50 nM results in large
standard deviations in KD calculations. Also, decreasing the
ratio of DNA : peptide further without lowering the DNA
concentration is not feasible due to problems in detection of
the isotope. Therefore we conducted a second series of EMSA
studies which involved a competitor DNA which allows for both
checking of nonspecific interactions and calculation of the KD.
EMSA for compounds 7 and 9 in the presence of 500 nM
competitor DNA reveal that nonspecific interactions do exist,
however the specificity of the compounds towards the CRE
sequence is still present to a large extent. This can be seen from
the gradual gel shift in contrast to the previous gel (Fig. 3B). In
support of this is that KD calculations from competition experi-
ments with 0.5–2 mM competitor DNA give values of 4–8 
10 nm for 7 and 1–3  102 nm for 9 (see ESI†). We can also state
here more conclusively that 7 is clearly not only the better DNA
binding construct but also shows greater specificity as com-
pared to 9.
A series of experiments were set up to investigate the cell up-
take capacity of the various synthetic constructs. For this
purpose the best DNA binding cholic acid based mimic 7 of
the GCN4 protein was resynthesized incorporating a fluores-
cein tag to give 14. The properties of this construct were
compared to the labelled but otherwise unmodified GCN4
peptide dimer 12 and monomer 11 as well as the monomeric
steroid conjugate 13. The toxicity (MTT assay), quantification of
uptake (flow cytometry) and intracellular localization of these
constructs were studied on RAW264.7 mouse macrophages,
which have been already used for cell penetration studies with
a similar GCN4 peptide.30 Compounds 12 and 14 showed a cell
viability at 0,25 mM of 88% and 86% respectively (ESI†) and
both are taken up at 37 1C but to a diﬀerent degree. There is
clearly an enhanced uptake when deoxycholic acid is used as a
scaﬀold, as seen from the mean fluorescence values obtained
by flow cytometry analysis, as they are more than four times
higher for 14 than for 12 (Fig. 4II). The monopodal cholic acid
derivative 13, although non-DNA binding and more hydropho-
bic, also exhibits enhanced uptake. However, a decreased
uptake is seen when the concentration is increased to 1 mM
(ESI†). This could be attributed to the denaturant like proper-
ties of the cholic acid. The most interesting results were
obtained when comparing the localisation of the DNA binding
cholic acid dimer 14 at 4 1C and 37 1C (Fig. 4IA and B). At 4 1C,
where endocytosis is blocked, only binding to the cell
membrane was observed. This resulted in a high percentage
of peptide positive cells (Fig. 4II left and middle). However, at
37 1C, whereby both passive and active uptake is possible, the
uptake is considerably higher as evidenced by the higher mean
cell fluorescence. This indicates that the deoxycholic acid
coupled peptides are mainly internalized via active transport
at 37 1C. The most likely ex-planation is that the peptides follow
an endocytotic pathway.
In conclusion, we here have illustrated a strategy to con-
jugate relatively long, unprotected peptides to bile acid scaf-
folds in a convergent manner. From the four models of the
GCN4 bZIP transcription factor presented, the one with the
most flexible linker (7) proved to be the best synthetic DNA
binder. This can be attributed to the fact that the linker allows

























Fig. 2 Deoxycholic acid derivatives for the substitution of the dimeriza-
tion domain with the corresponding peptides.
Fig. 3 (A) EMSA titration of the dipodal peptidosteroid conjugates 7 and
9 to the 50-labeled 32P-CRE sequence (50-CGG ATG ACG TCA TTT TTT
TTC-30) and its complementary strand (50-GAA AAA AAA TGA CGT CAT
CCG-3 0) at 5 nM: first lane in all the gels: pyrimidine strand (50-labeled
32P-CRE sequence). Lanes 2–9 contain peptide concentrations of 0, 0.05,
0.0625, 0.075, 0.0875, 0.1, 0.1125 and 0.125 mM for 7 and 9. (B) EMSA
titration of the dipodal peptidosteroid conjugates 7 and 9 to the 50-labeled
32P-CRE sequence (5-CGG ATG ACG TCA TTT TTT TTC-30) at 5 nM in the
presence of competitor DNA sequence (50-AGCAGAGGGCGTGGGGG-
AAAAGAAAAAAGATCCACCGGTCGCCAC-30) at 500 nM: first lane in all the
gels: pyrimidine strand. Lanes 2 and 20 to 5 and 50 contain peptide
concentrations of 0, 0.05, 0.125 and 0.312 mM for 7 and 9 respectively.
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tweezers which is less optimal in the case of the other linkers,
which may be too long, too short, or too inflexible. The binding
aﬃnity of 7 is comparable with that of earlier described models
of GCN4 TFs with KDs in the nM range, while the synthetic
route is considerably less complicated. In addition, compound
7 is more readily taken up by cells than non-steroid constructs
as evidenced by the uptake in RAW264.7 mouse macrophages.
This illustrates the particular properties of the peptide com-
bined with the steroid nucleus, which allows uptake at low
concentrations. Using four models of the GCN4 bZIP TF we
were able to identify some of the parameters that aﬀect dsDNA
recognition in synthetic constructs. Additionally we also for the
first time discuss and reveal the interesting cell-uptake proper-
ties of this type of peptidosteroid based TF mimics.
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Fig. 4 (I) Confocal microscopy of RAW264.7 cells incubated with (A) 14 at
4 1C, (B) 14 at 37 1C, (C) 12 at 4 1C, and (D) 12 at 37 1C at 0.25 mM (green
fluorescence signal). Cell nuclei were labeled with Hoechst (blue) and cell
membranes with AlexaFluor647 conjugated cholera toxin subunit B (red).
The lower panels only show the green fluorescence channel. (Scale bar =
20 mm). (II) Flow cytometry analysis of mean cell fluorescence (left) and
peptide positive cells (middle) of the synthesized compounds 12 and 14
incubated with RAW264.7 cells at 4 1C and 37 1C at 0.25 mM. Mean
fluorescence of compounds 12 and 14 at 0.25 mM and 1 mM.
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